Latest common stock for FRTX: $60K.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company). Positive growth indicates new issuance/dilution; negative growth indicates reductions/buybacks.
As of the most recent data (December 2023), FRTX shows a common stock of $60K. That compares with $3M in the prior-year period — down 98.0% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, FRTX's common stock is now $60K (was $3M) — a 98.0% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Fresh Tracks Therapeutics is outperforming or lagging.
Tracking FRTX's common stock over time shows whether Fresh Tracks Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $60K That compares with $3M in the prior-year period — down 98.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this common stock page, Stockcircle has Fresh Tracks Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect common stock (currently $60K) with ownership activity and broader fundamentals.
Fresh Tracks Therapeutics's common stock is $60K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.